ALZHEIMERS DRUGS MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America dominates  global Alzheimer's drugs market with an estimated market share of 40.3% in 2024. The region accounts for the largest market share due to presence of major pharmaceutical companies undertaking research and clinical trials for new drugs. Furthermore, aging population and rising prevalence of Alzheimer's disease in the region also drives the market growth. Countries like U.S. have also approved use of several disease-modifying drugs under their regulatory pathways, thus, providing boost to regional sales.

Asia Pacific region has emerged as the fastest growing market for Alzheimer's drugs. Asia Pacific market is expected to witness highest CAGR, owing to increasing focus of international drug makers to tap unmet needs. Countries like China and India are proving lucrative with their huge patient pool and growing healthcare expenditure. Local companies are also ramping up their R&D activities in collaboration with global innovators. This has led to higher availability of both generic and patented drugs across major Asian countries. Lack of stringent regulations compared to Western nations makes Asia Pacific region an attractive destination for clinical trials of new molecules.